IV Stem Cells 

• What they are: Living, fully intact, replicating cellular entities from umbilical cord

• The Mechanism: MSCs are structural “builders.” While they do not permanently engraft or turn into new organs, they physically home to areas of acute injury or chronic inflammation. Once there, they stay alive in the tissues for months, acting as continuous, smart “bioreactors” that release tailored healing signals in response to the microenvironment.

• Primary Benefit: Maximum potency for structural damage, deep joint repair, severe tissue degradation, and complex systemic conditions requiring a sustained, long-term cellular response.

IV Stem Cell Exosomes (Extracellular Vesicles / EVs)

• What they are: Non-living, acellular, microscopic lipid “bubbles” (30–150 nanometers) naturally secreted by stem cells.

• The Mechanism: Exosomes are pure “messengers.” They do not contain live cells, DNA, or the ability to replicate. Instead, they are packed with a concentrated payload of growth factors, cytokines, mRNA, and microRNA. They float through circulation, fuse with the patient’s existing cells, and instantly deliver “blueprints” instructing those native cells to downregulate inflammation and accelerate self-repair.

• Primary Benefit: High safety profile and immediate cellular signaling. Because they are non-living, they carry zero risk of replication or tumor formation, have exceptionally low immunogenicity.

Dezawa MuseCells® are a distinct, naturally occurring subset of stem cells isolated from mesenchymal tissue. Three properties set them apart from conventional MSCs — and from other pluripotent platforms such as embryonic stem cells and iPSCs:

Pluripotency: They can differentiate into virtually any cell type in the body — not just mesenchymal lineages. And they do this spontaneously in vivo, in response to the local tissue environment, without genetic engineering or chemical induction.

Homing: They actively seek out tissue damage by following sphingosine-1-phosphate (S1P), a biochemical distress signal produced by injured cells. This makes intravenous delivery clinically viable in a way it is not for conventional MSCs.

Immune privilege: They express HLA-G and produce immunomodulatory factors that prevent rejection by the host immune system — enabling allogeneic (donor-to-patient) use without HLA matching or immunosuppressive therapy.

A fourth property — non-tumorigenicity — distinguishes them from other pluripotent platforms. Despite genuine pluripotency, Dezawa MuseCells® do not form teratomas. This is grounded in active molecular regulation: low telomerase activity, somatic-like cell cycle gene expression, and the Let-7/Lin28 microRNA axis that keeps oncogenic targets suppressed.

Phase II clinical trials in Japan — the most extensive Dezawa MuseCell® clinical dataset — used 15 million cells delivered intravenously as the primary dose. This figure reflects Japanese patient population size and body weight distributions.

For western patient populations, 20 million cells IV has become the standard starting dose used by MCI-authorized clinical partners, reflecting a proportional adjustment for larger average body size. This figure is not drawn from a Phase III dose-comparison trial — no such trial has been completed — and represents clinical consensus within the authorized practitioner network.

Published data and clinical experience support the following practical framework:

• Standard IV dose: 20 million – 100 million cells

• Local orthopedic injection dose: 5–20 million cells generally, based on provider discretion

IV is supported by the broadest published clinical trial evidence and works via the systemic homing mechanism. It is preferred for neurological, cardiac, immunological, and systemic indications, and any condition without a single accessible anatomical target.

Local injection is preferred when the primary treatment target is a specific, accessible orthopedic or musculoskeletal site. Clinical experience indicates stronger and more reliable local effect at the target site. Note that local injection also produces some systemic effect — consistent with the paracrine and immune properties of Dezawa MuseCells®.

Combined approach (IV + local injection) is reasonable for complex cases where both concentrated local effect and systemic distribution are clinically warranted. This has not been evaluated in a controlled trial.